A new study from Karolinska Institutet and the Karolinska University Hospital indicates that only a rather small proportion of individuals attending a specialized memory clinic have an Alzheimer’s disease-type biomarker profile and could be considered eligible for novel disease-modifying treatments targeting amyloid.
The study, published online on September 21, 2022, in Neurology®, the medical journal of the American Academy of Neurology, was conducted as part of the strategic research collaboration between Karolinska Institutet and Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Link to publication:
https://n.neurology.org/content/early/2022/09/21/WNL.0000000000201043
Contact information:
Dr. Anna Rosenberg, anna.rosenberg@ki.se, Prof. Miia Kivipelto, miia.kivipelto@ki.se
